Continuous measurement of circulating biomarkers is enabled by an emerging class of biosensors.[188, 189] Wearable continuous glucose monitors (CGM) have been clinically adopted in the T1D community, thus reducing the burden of patient self‐monitoring and ensuring that patients remain in a euglycemic range.[190, 191] A state‐of‐the‐art CGM worn after graft delivery could help correlate graft function to physiologic cell released insulin responses and help tailor and taper exogenous insulin delivery as the SC‐islet graft matures over time. The gene discussed is INS; the disease is type 1 diabetes mellitus.